Treatment of Chronic Lymphocytic Leukemia With a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-08-2099
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia

ISRN Oncology
2014English

Comparative Efficacy of Chronic Lymphocytic Leukemia Treatment With or Without Rituximab

Oncogematologiya
OncologyHematology
2019English

Cytokine Contents in Chronic Lymphocytic Leukemia: Association With ZAP70 Expression

Turkish Journal of Haematology
Hematology
2016English

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (Literature Review)

Oncogematologiya
OncologyHematology
2018English

Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using Quantitative Fluorescence Cytometry

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

Chronic Lymphocytic Leukemia

Current Opinion in Hematology
Hematology
1998English

Chronic Lymphocytic Leukemia

Orvosi Hetilap
Medicine
2008English

Chronic Lymphocytic Leukemia

ASH Image Bank
2003English

Chronic Lymphocytic Leukemia

Molecular and Translational Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy